How a Clinical Trial Is Structured: Phases and Types
Part of Clinical Research Coordinator (CRC) Training: Clinical Research Foundations.
About 6 minutes. Free, in your language, no account needed.
Why this matters
Participants ask two questions constantly. "Has this drug been tested before?" and "Am I a guinea pig?" You cannot answer either one unless you know where your trial sits in the sequence. A coordinator who can explain the phase of their own study earns trust in about thirty seconds.
The phase also changes your daily work. An early-phase study may keep a participant on site for twelve hours. A late-phase study may see them four times in a year.
The phases of a drug trial
Drug development runs in stages. Each stage answers a different question, and each one is larger than the last.
| Phase | Main question | Typical participants |
|---|---|---|
| Preclinical | Is there any reason to test this in people at all? | None. Laboratory and animal work. |
| Phase I | Is it safe, and what dose can people tolerate? | A small group, often healthy volunteers. In serious illness such as cancer, patients instead. |
| Phase II | Does it appear to work, and is it still safe? | A larger group who have the condition. |
| Phase III | Is it better than what we already use? | A large group, often across many countries. |
| Phase IV | What do we learn once it is in ordinary use? | People taking the approved product. |
Two clarifications that coordinators are often asked about.
Phase I does not mean untested. By the time a product reaches a person, it has been through laboratory and animal work, and a regulator has reviewed that work before allowing human dosing.
Phase IV is still research. A product on the market can still be studied. Rare harms often only appear once very large numbers of people have taken something.
Device trials and vaccine trials use related but not identical staging. If you work on a device study, ask which framework your protocol uses rather than assuming the drug phases apply.
Types of study by purpose
Phases describe how far along a drug is. A different set of words describes what a study is trying to do.
- Treatment or interventional trials test whether an intervention helps people who already have a condition.
- Prevention trials test whether something stops a condition from developing. Participants are often healthy but at raised risk.
- Diagnostic trials test whether a new test or scan identifies a condition more accurately or earlier.
- Screening trials test whether looking for a condition in people without symptoms does more good than harm.
- Quality of life trials, sometimes called supportive care trials, test whether something improves how a person lives with a condition, rather than curing it.
- Observational studies record what happens without assigning treatment.
The same product can appear in several of these. A drug may be tested as a treatment in one study and as a prevention in another, with completely different eligibility rules.
The life of a single trial
Whatever the phase, a trial passes through the same stages at your site. You will meet each of them in this course.
- Design and approval. The sponsor writes the protocol. A regulator and an ethics committee review it.
- Site selection and start-up. The sponsor decides whether your site can run the study. The contract is signed, documents are collected, staff are trained. Module 5 covers this.
- Recruitment and enrollment. You find, screen and consent participants. Modules 6 and 7.
- Conduct. Visits happen, data are recorded, safety events are reported. Modules 8 and 9.
- Close-out and archiving. The last participant finishes, the data are locked, records are archived. Module 10.
Stage 5 is the one new coordinators underestimate. A study you enrolled in year one may still be generating work for you in year four.
Blinding, in one paragraph
You will hear a study described as open-label, single-blind or double-blind. Open-label means everyone knows which treatment a participant is receiving. Single-blind usually means the participant does not know. Double-blind means neither the participant nor the site staff know. Blinding exists to stop expectation from changing what people report and what staff record. Module 4, Lesson 2 explains how it is done and what you must never do to break it.
In practice
Nadia coordinates VT-201, the Vantis Pharma hypertension trial at Northside Clinic. It is a Phase III, double-blind, randomized trial comparing a new tablet with an established one.
A prospective participant, Mr. Adeyemi, asks whether he will be the first person ever to take the new tablet. Nadia explains the sequence: laboratory work, then a small safety study in volunteers, then a study in people with high blood pressure, and now this study, which is the largest and compares the new tablet against the treatment he would otherwise be offered.
He then asks which tablet he will get. Nadia explains that neither he nor she will know, that a computer will decide, and that his own doctor can be told immediately if there is ever a medical reason to find out.
Mr. Adeyemi says nobody had explained it that way before. He enrolls.
Knowing your study's phase is not trivia. It is how you answer the only two questions participants really ask.
Key takeaways
- Drug trials run in phases: Phase I asks about safety and tolerated dose, Phase II about early effect, Phase III about comparison with existing care, and Phase IV about use after approval.
- Phase I is not the first test of a product, because laboratory and animal work and a regulatory review come before any person is dosed.
- Studies are also classified by purpose — treatment, prevention, diagnostic, screening, quality of life, and observational — and the same product may appear in several types.
- Every trial passes through the same five stages at a site: approval, start-up, recruitment, conduct, and close-out with archiving.
- Blinding hides treatment allocation from the participant, and in a double-blind study from site staff too, so that expectation does not shape the results.